Opinions+ By Jonathan P. Gertler Why medtech is a different beast than biotech in the life sciences pack
Opinions+ By STAT staff From the C-Suite: Biotech execs share their best interview questions — and the answers they want to hear
Opinions+ By Andrew Bolt and Sonal Shah Unprecedented development of Covid-19 vaccines, treatments points to biopharma’s future
First Opinion By Cecile Riboud In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment
Opinions+ By Christopher Leo, Christian Thienel, and Brendan Wang Early price setting, other market access planning is key for early-stage drug, device companies
Opinions+ By Nick Stephens How to create successful leadership teams for cell and gene therapy companies
Opinions+ By Christopher Boone and Viraj Narayanan How to apply real-world evidence to outsmart cancer
Opinions+ By Leslie Loveless To recruit top life sciences executives, companies need solid strategies in 2019
Opinions+ By Vijay Ramakrishnan and Edwin P. Ching Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions
Opinions+ By Elizabeth Cooney Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros
Opinions+ By Elizabeth Cooney Tell us what you really think: A survey on drug prices, biotech, and Alex Azar
Opinions+ By Elizabeth Cooney Industry insiders are upbeat about 2018, but that doesn’t mean more hiring
Opinions+ By STAT staff From the C-Suite: How to learn leadership skills from mentors as diverse as Gen. Patton — and mom
Opinions+ By Robert M. Thomas Jr. Doctors, beware: Prosecutors are zooming in on health care fraud as opioid crisis mounts